title: New Perspectives in Pediatric Neurology-Multiple Sclerosis.
abstract: With the creation of consensus definitions for pediatric multiple sclerosis (MS) and other acquired demyelinating syndromes, there has been an increased recognition, improved collaboration, and expanded access to care for children with central nervous system demyelination. As a result, clinicians and researchers have been able to learn more about clinical features specific to pediatric MS, the associated genetic and environmental risk factors, and its prognosis and comorbidities. Treatment options have also expanded significantly in the past few years and insight has been gained into the challenges with adherence and tolerability of these medications in the pediatric population. Emerging therapies are now being studied in the context of pediatric clinical trials and may prove to be safe and effective options for patients with aggressive disease.
authors.affiliation: Division of Neurology, The Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA. Electronic address: NARULAS@email.chop.edu.
authors.forename: Sona
authors.initials: S
authors.lastname: Narula
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D032921:Consensus; D003937:Diagnosis, Differential; D018450:Disease Progression; D004673:Encephalomyelitis, Acute Disseminated / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000068556:Interferon beta-1a / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis
chemical_list: D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D000068556:Interferon beta-1a